Sofosbuvir / Velpatasvir

Carbamazepine

Combination not recommended.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Carbamazepine may induce CYP 3A4 and P-gp and decrease the plasma concentration of Sofosbuvir / Velpatasvir.

Sofosbuvir / Velpatasvir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Do not administer with potent P-gp inducers or with moderate to potent CYP2B6, 2C8 or 3A4 inducers.

Alternative solution(s)

Carbamazepine

Pharmacodynamic effects

Recommendations

Association not recommended.

Alternative solution(s)

Gabapentin, pregabalin, levetiracetam, brivaracetam, or valproic acid

Monitor

Tests

Pharmacokinetic parameters

Comment

Reference
  • 3250
    Sofosbuvir/Velpatasvir (Epclusa), Gilead Sciences, Ontario, Canada, 5 novembre 2020.